Geode Capital Management
CTSO icon

Geode Capital Management’s Cytosorbents Corp CTSO Stock Holding History

Geode Capital Management’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Sell
602,059
-105,203
-15% -$55.6K ﹤0.01% 3871
2026
Q1 		$401K Buy
707,262
+103,495
+17% +$70.6K ﹤0.01% 3666
2025
Q4 		$386K Buy
603,767
+2,316
+0.4% +$1.78K ﹤0.01% 3687
2025
Q3 		$562K Hold
601,451
– – ﹤0.01% 3576
2025
Q2 		$770K Sell
601,451
-12,404
-2% -$12.5K ﹤0.01% 3415
2025
Q1 		$614K Buy
613,855
+139,702
+29% +$147K ﹤0.01% 3471
2024
Q4 		$432K Buy
474,153
+7,095
+2% +$6.96K ﹤0.01% 3647
2024
Q3 		$701K Buy
467,058
+32,415
+7% +$35.5K ﹤0.01% 3477
2024
Q2 		$306K Sell
434,643
-3,654
-0.8% -$3.17K ﹤0.01% 3758
2024
Q1 		$416K Buy
438,297
+73,377
+20% +$71.4K ﹤0.01% 3679
2023
Q4 		$405K Hold
364,920
– – ﹤0.01% 3694
2023
Q3 		$686K Sell
364,920
-6,788
-2% -$19.5K ﹤0.01% 3488
2023
Q2 		$1.33M Hold
371,708
– – ﹤0.01% 3244
2023
Q1 		$1.25M Hold
371,708
– – ﹤0.01% 3243
2022
Q4 		$576K Buy
371,708
+3,189
+0.9% +$4.73K ﹤0.01% 3600
2022
Q3 		$501K Buy
368,519
+909
+0.2% +$1.77K ﹤0.01% 3726
2022
Q2 		$805K Sell
367,610
-335,105
-48% -$769K ﹤0.01% 3519
2022
Q1 		$2.24M Buy
702,715
+8,800
+1% +$31.5K ﹤0.01% 3209
2021
Q4 		$2.91M Sell
693,915
-3,250
-0.5% -$18.2K ﹤0.01% 3186
2021
Q3 		$5.66M Buy
697,165
+3,332
+0.5% +$27.1K ﹤0.01% 2836
2021
Q2 		$5.24M Buy
693,833
+36,374
+6% +$306K ﹤0.01% 2868
2021
Q1 		$5.71M Buy
657,459
+89,052
+16% +$849K ﹤0.01% 2726
2020
Q4 		$4.53M Buy
568,407
+41,552
+8% +$348K ﹤0.01% 2655
2020
Q3 		$4.2M Buy
526,855
+69,098
+15% +$623K ﹤0.01% 2500
2020
Q2 		$4.53M Buy
457,757
+35,585
+8% +$327K ﹤0.01% 2392
2020
Q1 		$3.26M Buy
422,172
+62,520
+17% +$316K ﹤0.01% 2398
2019
Q4 		$1.38M Buy
359,652
+6,891
+2% +$30.1K ﹤0.01% 3154
2019
Q3 		$1.77M Buy
352,761
+5,922
+2% +$34.5K ﹤0.01% 3004
2019
Q2 		$2.29M Buy
346,839
+24,454
+8% +$168K ﹤0.01% 2860
2019
Q1 		$2.44M Buy
322,385
+20,887
+7% +$163K ﹤0.01% 2735
2018
Q4 		$2.44M Buy
301,498
+16,679
+6% +$166K ﹤0.01% 2658
2018
Q3 		$3.67M Buy
284,819
+45,620
+19% +$572K ﹤0.01% 2562
2018
Q2 		$2.73M Buy
239,199
+94,317
+65% +$893K ﹤0.01% 2683
2018
Q1 		$1.02M Buy
144,882
+11,320
+8% +$85.5K ﹤0.01% 3113
2017
Q4 		$868K Buy
133,562
+6,437
+5% +$40.9K ﹤0.01% 3155
2017
Q3 		$788K Hold
127,125
– – ﹤0.01% 3200
2017
Q2 		$546K Buy
127,125
+242
+0.2% +$1.06K ﹤0.01% 3326
2017
Q1 		$570K Buy
126,883
+606
+0.5% +$3.39K ﹤0.01% 3257
2016
Q4 		$688K Buy
126,277
+404
+0.3% +$2.21K ﹤0.01% 3159
2016
Q3 		$805K Buy
125,873
+101
+0.1% +$525 ﹤0.01% 3061
2016
Q2 		$572K Hold
125,772
– – ﹤0.01% 3169
2016
Q1 		$493 Sell
125,772
-101
-0.1% -$438 ﹤0.01% 3245
2015
Q4 		$701K Sell
125,873
-1,673
-1% -$11.4K ﹤0.01% 3090
2015
Q3 		$804K Buy
127,546
+202
+0.2% +$1.35K ﹤0.01% 2990
2015
Q2 		$781K Buy
127,344
+101
+0.1% +$687 ﹤0.01% 3017
2015
Q1 		$1.68M Buy
+127,243
New +$1.31M ﹤0.01% 2552

Other funds holding CTSO

AC
Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $814M AUM 32.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CBU
CIBC Bancorp USA Chicago, Illinois $82.3B AUM

Geode Capital Management's CTSO Position: Q2 2026 in Review

Geode Capital Management reduced its Cytosorbents Corp (CTSO) stake by 15% in Q2 2026, selling an estimated $55.6K and leaving 602,059 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #3871.

Geode Capital Management first reported a position in CTSO in Q1 2015 and has held it in 46 quarters since. The position peaked at $5.71M in Q1 2021. 42 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.

  • Geode Capital Management held 602,059 shares of Cytosorbents Corp worth $225K as of Q2 2026.
  • Geode Capital Management sold 105,203 Cytosorbents Corp shares in Q2 2026, an estimated $55.6K.
  • Cytosorbents Corp made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3871 holding.
  • Geode Capital Management first reported a position in Cytosorbents Corp in Q1 2015 and has held it in 46 quarters since.
  • Geode Capital Management's Cytosorbents Corp position peaked at $5.71M in Q1 2021.
  • 42 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.